Original Research

Comparing Imatinib and Nilotinib in the Treatment of Newly Diagnosed Chronic Myeloid Leukemia in Patients of Sandeman Provincial Hospital, Quetta, Pakistan

Afia Haque
Department of Internal Medicine, Sandeman Provincial Hospital, Quetta
Syed Khalid Shah
Department of Internal Medicine, Sandeman Provincial Hospital, Quetta
Humaira Rahim
Department of Internal Medicine, Sandeman Provincial Hospital, Quetta
Abdul Wahid
Department of Internal Medicine, Sandeman Provincial Hospital, Quetta

✉ Correspondence: Afia Haque Email: dusk786@hotmail.com

DOI https://doi.org/10.70302/jpsim.v3i1.2207
Volume: 3, Issue 1 Pages: 36–40 Published: 15 Mar 2022
Received: 01 Nov 2021 Accepted: 27 Dec 2021 Published Online: 15 Mar 2022

Abstract

Objective

To compare the effectiveness of Imatinib and Nilotinib as first-line drug in the treatment of chronic myeloid
leukemia.

Methods

The study was conducted at Medicine Unit III, S.P.H, Quetta, from April 2019 to 2020. Study was commenced
after taking approval from ethical committee of the institute. Newly diagnosed, treatment naïve, chronic myeloid
leukemia patients visiting Medical OPD, Emergency and Medicine ward fulfilling the inclusion criteria. Exclusion criteria
was strictly followed to control confounder and bias in the study. Patients were randomly divided into two groups, one
started on Imatinib and other Nilotinib, were followed up at 3, 6 and 11 months with CBC and molecular response by bcrabl PCR on blood or bone marrow. Informed consent was taken from all the patients prior to the commencement of the
study and thpeir information was kept confidential.

Results

Of the 149 patients in Imatinib group, 99 showed response to treatment with 36% achieving MMR in 9 to 12
months, while 130 patients on Nilotinib showed drug effectiveness with 52% achieving MMR within 9 to 12 months,
mainly at 9 months of treatment.

Conclusion

The study endorses that Nilotinib is better than Imatinib in the treatment of CP-CML, and hence can be used
as first line therapy.

Keywords
CP-CML Imatinib Nilotinib MMR CCyR

How to Cite This Article

Haque A, Shah SK, Rahim H, Wahid A. Comparing Imatinib and Nilotinib in the Treatment of Newly Diagnosed Chronic Myeloid Leukemia in Patients of Sandeman Provincial Hospital, Quetta, Pakistan. J Pak Soc Intern Med. 2022;3(1):36–40. doi:10.70302/jpsim.v3i1.2207

⭳ Download PDF

Conflict of Interest

All authors declare no competing interests.

Disclosed in accordance with ICMJE and COPE guidelines.

Funding

No specific funding was received for this research.

Funder information follows the Crossref Funder Registry standard.

References

  1. Maxine A. Papadakis, Stephen J. McPhee MWR. Current medical diagnosis and treatment 2017. In: 56th Editi. Mc Graw Hill; 2017. p. 523–4.
  2. Cortes HKJ. Chronic Myeloid Leukemia | Harrison’s Principles of Internal Medicine, 19e | AccessMedicine | McGraw-Hill Medical. In [cited 2019 Dec 17]. Available from: https://accessmedicine.mhmedical.com/content.aspx?bookid=1130&sectionid=79731824
  3. Kantarjian HM, Hochhaus A, Saglio G, Souza C De, Flinn IW, Stenke L, et al. Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial. Lancet Oncol. 2011 Sep;12(9):841–51.
  4. Guérin A, Chen L, Ionescu-Ittu R, Marynchenko M, Nitulescu R, Hiscock R, et al. Impact of low-grade adverse events on health-related quality of life in adult patients receiving imatinib or nilotinib for newly diagnosed Philadelphia chromosome positive chronic myelogenous leukemia in chronic phase. Curr Med Res Opin. 2014 Nov 1;30(11):2317–28.
  5. Saglio G, Kim DW, Issaragrisil S, Le Coutre P, Etienne G, Lobo C, et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med. 2010 Jun 17;362(24):2251–9.
  6. Chronic myeloid leukaemia (CML) - Leukaemia Foundation [Internet]. [cited 2022 Jan 4]. Available from: https://www.leukaemia.org.au/blood-cancer-information/types-of-blood-cancer/leukaemia/chronic-myeloid-leukaemia/
  7. Yun S, Vincelette ND, Segar JM, Dong Y, Shen Y, Kim DW, et al. Comparative Effectiveness of Newer Tyrosine Kinase Inhibitors Versus Imatinib in the First-Line Treatment of Chronic-Phase Chronic Myeloid Leukemia Across Risk Groups: A Systematic Review and Meta-Analysis of Eight Randomized Trials. Clin Lymphoma, Myeloma Leuk. 2016 Jun 1;16(6):e85–94.
  8. Erba HP, Pham DC, Zaiden R, Vu H, Tai S. Improving frontline treatment for chronic myeloid leukemia: emerging evidence for use of nilotinib and dasatinib. Clin Adv Hematol Oncol [Internet]. 2011 Oct [cited 2019 Dec 17];9(10):734–45. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22252576
  9. Zaidi U, Kaleem B, Borhany M, Maqsood S, Fatima N, Sufaida G, et al. <p>Early and sustained deep molecular response achieved with nilotinib in high Sokal risk chronic myeloid leukemia patients</p>. Cancer Manag Res [Internet]. 2019 Feb 15 [cited 2022 Jan 5];11:1493–502. Available from: https://www.dovepress.com/early-and-sustained-deep-molecular-response-achieved-with-nilotinib-in-peer-reviewed-fulltext-article-CMAR
  10. Kantarjian HM, Hughes TP, Larson RA, Kim DW, Issaragrisil S, le Coutre P, et al. Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis. Leuk 2021 352 [Internet]. 2021 Jan 7 [cited 2022 Jan 5];35(2):440–53. Available from: https://www.nature.com/articles/s41375-020-01111-2
  11. Cortes JE, Jones D, O’Brien S, Jabbour E, Konopleva M, Ferrajoli A, et al. Nilotinib as front-line treatment for patients with chronic myeloid leukemia in early chronic phase. J Clin Oncol. 2010 Jan 20;28(3):392–7.
  12. Annunziata M, Bonifacio M, Breccia M, Castagnetti F, Gozzini A, Iurlo A, et al. Current Strategies and Future Directions to Achieve Deep Molecular Response and Treatment-Free Remission in Chronic Myeloid Leukemia. Front Oncol. 2020 Jun 2;10:883.

Reference list indexed for Google Scholar and ResearchGate. DOI links resolve via doi.org.

CC BY CC BY 4.0 This article is published under the Creative Commons Attribution 4.0 International License. May be shared and adapted with attribution. © 2022 Journal of Pakistan Society of Internal Medicine.
📃 In This Issue View All
Original Article Cervical Cancer Screening Awareness Among Rural Women in Punjab Bibi S, Anjum R, Hassan F Review Article Antibiotic Resistance Patterns in Community-Acquired Pneumonia: Emerging Trends Hussain I, Farooq Z Original Article Impact of Diabetes Mellitus on Post-Operative Wound Healing in General Surgery Siddiqui FA, Noor M, Akhtar W Original Article Serum Ferritin as a Prognostic Marker in COVID-19 Severity: A Hospital-Based Study Rehman N, Sheikh I, Javed K Original Article Outcomes of Laparoscopic Cholecystectomy in Acute Cholecystitis: A Retrospective Analysis Raza SH, Butt N, Qureshi AM
👥 More by These Authors
Original Article Comparison of Ultrasound-Guided versus Landmark-Based Central Venous Catheter Insertion Zafar S, Gillani SA Original Article Neonatal Sepsis: Bacteriological Profile and Antibiogram in a Tertiary Care Hospital Iqbal M, Rashid T Review Article Statin Therapy in Non-Alcoholic Fatty Liver Disease: A Systematic Review Nawaz F, Cheema HA, Mehmood Y Review Article Thyroid Disorders in Pregnancy: Clinical Implications and Management Strategies Baig BI, Usman A
🔗 Related Articles By Keywords
Original Article Impact of Diabetes Mellitus on Post-Operative Wound Healing in General Surgery Siddiqui FA, Noor M, Akhtar W Original Article Serum Ferritin as a Prognostic Marker in COVID-19 Severity: A Hospital-Based Study Rehman N, Sheikh I, Javed K Original Article Outcomes of Laparoscopic Cholecystectomy in Acute Cholecystitis: A Retrospective Analysis Raza SH, Butt N, Qureshi AM Original Article Prevalence of Hypertension Among Urban Adults in Pakistan: A Cross-Sectional Study Khan TM, Ahmed S, Malik RA